These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 32333847)

  • 21. Anthrax vaccine adsorbed: further evidence supporting continuing the vaccination series rather than restarting the series when doses are delayed.
    Pittman PR; Cavicchia MA; Kingsbury JL; Johnson NA; Barrera-Oro JG; Schmader T; Korman L; Quinn X; Ranadive M
    Vaccine; 2014 Sep; 32(39):5131-9. PubMed ID: 24837771
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trial.
    Madhi SA; Cutland CL; Jose L; Koen A; Govender N; Wittke F; Olugbosi M; Meulen AS; Baker S; Dull PM; Narasimhan V; Slobod K
    Lancet Infect Dis; 2016 Aug; 16(8):923-34. PubMed ID: 27139805
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and immunogenicity of a plant-derived recombinant protective antigen (rPA)-based vaccine against Bacillus anthracis: A Phase 1 dose-escalation study in healthy adults.
    Paolino KM; Regules JA; Moon JE; Ruck RC; Bennett JW; Remich SA; Mills KT; Lin L; Washington CN; Fornillos GA; Lindsey CY; O'Brien KA; Shi M; Mark Jones R; Green BJ; Tottey S; Chichester JA; Streatfield SJ; Yusibov V
    Vaccine; 2022 Mar; 40(12):1864-1871. PubMed ID: 35153091
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cross-species prediction of human survival probabilities for accelerated anthrax vaccine absorbed (AVA) regimens and the potential for vaccine and antibiotic dose sparing.
    Stark GV; Sivko GS; VanRaden M; Schiffer J; Taylor KL; Hewitt JA; Quinn CP; Nuzum EO
    Vaccine; 2016 Dec; 34(51):6512-6517. PubMed ID: 27558619
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized, double-blind, active-controlled study evaluating the safety and immunogenicity of three vaccination schedules and two dose levels of AV7909 vaccine for anthrax post-exposure prophylaxis in healthy adults.
    Hopkins RJ; Kalsi G; Montalvo-Lugo VM; Sharma M; Wu Y; Muse DD; Sheldon EA; Hampel FC; Lemiale L
    Vaccine; 2016 Apr; 34(18):2096-105. PubMed ID: 26979136
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans.
    Pittman PR; Kim-Ahn G; Pifat DY; Coonan K; Gibbs P; Little S; Pace-Templeton JG; Myers R; Parker GW; Friedlander AM
    Vaccine; 2002 Jan; 20(9-10):1412-20. PubMed ID: 11818160
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lethal factor antibodies contribute to lethal toxin neutralization in recipients of anthrax vaccine precipitated.
    Dumas EK; Garman L; Cuthbertson H; Charlton S; Hallis B; Engler RJM; Choudhari S; Picking WD; James JA; Farris AD
    Vaccine; 2017 Jun; 35(26):3416-3422. PubMed ID: 28504191
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009.
    Wright JG; Quinn CP; Shadomy S; Messonnier N;
    MMWR Recomm Rep; 2010 Jul; 59(RR-6):1-30. PubMed ID: 20651644
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Raxibacumab: potential role in the treatment of inhalational anthrax.
    Kummerfeldt CE
    Infect Drug Resist; 2014; 7():101-9. PubMed ID: 24812521
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial.
    Assouline S; Buccheri V; Delmer A; Gaidano G; Trneny M; Berthillon N; Brewster M; Catalani O; Li S; McIntyre C; Sayyed P; Badoux X
    Lancet Haematol; 2016 Mar; 3(3):e128-38. PubMed ID: 26947201
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunological effect of administration of sequential doses of Haemophilus influenzae type b and pneumococcal conjugate vaccines in the same versus alternating limbs in the routine infant immunisation schedule: an open-label randomised controlled trial.
    Iro MA; Khatami A; Marshall AS; Pace D; Voysey M; McKenna J; Campbell D; Attard-Montalto S; Finn A; White C; Faust SN; Kent A; Heath PT; MacLeod E; Stanford E; Findlow H; Almond R; Bai X; Borrow R; Snape MD; Pollard AJ
    Lancet Infect Dis; 2015 Feb; 15(2):172-80. PubMed ID: 25577661
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anthrax Vaccine Precipitated Induces Edema Toxin-Neutralizing, Edema Factor-Specific Antibodies in Human Recipients.
    Dumas EK; Gross T; Larabee J; Pate L; Cuthbertson H; Charlton S; Hallis B; Engler RJM; Collins LC; Spooner CE; Chen H; Ballard J; James JA; Farris AD
    Clin Vaccine Immunol; 2017 Nov; 24(11):. PubMed ID: 28877928
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of body mass index, pre-vaccination serum progesterone levels and anti-anthrax protective antigen immunoglobulin G on injection site adverse events following anthrax vaccination in women.
    Zhang Y; Martin SW; Rose CE; Biagini RE; Franzke LH; Smith JP; Sammons DL; Robertson SA; McNeil MM
    Pharmacoepidemiol Drug Saf; 2008 Nov; 17(11):1060-7. PubMed ID: 18781705
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine.
    Xie H; Gursel I; Ivins BE; Singh M; O'Hagan DT; Ulmer JB; Klinman DM
    Infect Immun; 2005 Feb; 73(2):828-33. PubMed ID: 15664922
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparisons of the humoral and cellular immunity induced by live A16R attenuated spore and AVA-like anthrax vaccine in mice.
    Lv J; Zhang YY; Lu X; Zhang H; Wei L; Gao J; Hu B; Hu WW; Hu DZ; Jia N; Feng X
    Biologicals; 2017 Mar; 46():130-138. PubMed ID: 28215694
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Factors influencing laboratory workers' decisions to accept or decline anthrax vaccine adsorbed (AVA): results of a decision-making study in CDC's anthrax vaccination program.
    Fowler GL; Baggs JM; Weintraub ES; Martin SW; McNeil MM; Gust DA
    Pharmacoepidemiol Drug Saf; 2006 Dec; 15(12):880-8. PubMed ID: 16924600
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and immunogenicity of Px563L, a recombinant anthrax vaccine candidate, in a two-dose regimen for post-exposure prophylaxis in healthy adults.
    Schneider JC; Chen HC; Bautista E; Retallack D
    Vaccine; 2021 Oct; 39(42):6333-6339. PubMed ID: 34544599
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Towards a human oral vaccine for anthrax: the utility of a Salmonella Typhi Ty21a-based prime-boost immunization strategy.
    Baillie LW; Rodriguez AL; Moore S; Atkins HS; Feng C; Nataro JP; Pasetti MF
    Vaccine; 2008 Nov; 26(48):6083-91. PubMed ID: 18805452
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of two schedules of two-dose priming with the ten-valent pneumococcal conjugate vaccine in Nepalese children: an open-label, randomised non-inferiority controlled trial.
    Kandasamy R; Gurung M; Thorson S; Yu LM; Galal U; Voysey M; Kelly S; Wahl B; Berbers G; Finnegan K; Ansari I; Paudel K; Murdoch DR; O'Brien KL; Kelly DF; Goldblatt D; Shrestha S; Pollard AJ
    Lancet Infect Dis; 2019 Feb; 19(2):156-164. PubMed ID: 30635252
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase 3 trial evaluating the immunogenicity and safety of a three-dose BioThrax® regimen for post-exposure prophylaxis in healthy adults.
    Hopkins RJ; Howard C; Hunter-Stitt E; Kaptur PE; Pleune B; Muse D; Sheldon E; Davis M; Strout C; Vert-Wong K
    Vaccine; 2014 Apr; 32(19):2217-24. PubMed ID: 24613523
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.